PT  - JOURNAL ARTICLE
AU  - Gerhard Levy
AU  - Tai Matsuzawa
TI  - PHARMACOKINETICS OF SALICYLAMIDE ELIMINATION IN MAN
DP  - 1967 May 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 285--293
VI  - 156
IP  - 2
4099  - http://jpet.aspetjournals.org/content/156/2/285.short
4100  - http://jpet.aspetjournals.org/content/156/2/285.full
SO  - J Pharmacol Exp Ther1967 May 01; 156
AB  - The pharmacokinetics of salicylamide elimination has been studied in healthy adult males and in two infants. Salicylamide is eliminated mainly by biotransformation to the glucuronide and the sulfate. The fraction of a dose which is excreted as salicylamide sulfate decreases with increasing dose, whereas the fraction excreted as glucuronide increases with increasing dose. The maximum excretion rate of salicylamide sulfate approaches a limiting value when 0.6 to 1.0 g of salicylamide is administered orally in rapidly absorbed form (solution) to adults. The limiting factor appears to be the availability of sulfate, since concomitant administration of L-cysteine increases the maximum excretion rate and the total excreted amount of salicylamide sulfate. Gentisamide glucuronide is a minor metabolite which appears in significant amounts only when salicylamide sulfate formation is restricted by the limited capacity of this process. Salicylamide in slowly absorbed form (pellets) yields larger amounts of salicylamide sulfate than the same dose in rapidly absorbed form (solution). These findings explain many of the apparent conflicts in previous reports on the metabolic fate of salicylamide in man, and they demonstrate that the metabolic fate of a drug which is eliminated by competing apparent zero-and first-order processes is a function of dose and dosage form, among other factors. © 1967 by The Williams & Wilkins Company